Natasha D Durham Selected Research

Infections

1/2020	P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion.
1/2020	Real-Time Analysis of Individual Ebola Virus Glycoproteins Reveals Pre-Fusion, Entry-Relevant Conformational Dynamics.
1/2019	P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1β in a Human Tonsil Explant Model.
3/2016	A high throughput Cre-lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry.
1/2016	Measuring T Cell-to-T Cell HIV-1 Transfer, Viral Fusion, and Infection Using Flow Cytometry.
9/2015	HIV-1 Cell-Free and Cell-to-Cell Infections Are Differentially Regulated by Distinct Determinants in the Env gp41 Cytoplasmic Tail.
10/2014	P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.
12/2013	Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells.
7/2012	Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Natasha D Durham Research Topics

Disease

9	Infections 01/2020 - 07/2012
2	Inflammation (Inflammations) 01/2019 - 10/2014
2	HIV Infections (HIV Infection) 03/2016 - 10/2014
1	Virus Diseases (Viral Diseases) 10/2014

Drug/Important Bio-Agent (IBA)

2	Glycoproteins (Glycoprotein)IBA 01/2020 - 09/2015
2	Purinergic P2X1 ReceptorsIBA 01/2020 - 01/2019
2	3- (5- (2,3- dichlorophenyl)- 1H- tetrazol- 1- yl)methylpyridineIBA 01/2020 - 01/2019
2	4,4,',4'',4'''- (carbonylbis(imino- 5,1,3- benzenetriylbis(carbonylimino)))tetrakis(benzene- 1,3- disulfonate)IBA 01/2020 - 01/2019
2	Purinergic Receptors (Receptors, Purine)IBA 01/2019 - 10/2014
2	Neutralizing AntibodiesIBA 01/2016 - 07/2012
1	Broadly Neutralizing AntibodiesIBA 01/2020
1	NF 279IBA 01/2020
1	Zidovudine (Retrovir)FDA LinkGeneric 01/2019
1	CytokinesIBA 01/2019
1	Purinergic P2X7 ReceptorsIBA 01/2019
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2019
1	Interleukin-10 (Interleukin 10)IBA 01/2019
1	Biological ProductsIBA 03/2016
1	NigericinIBA 03/2016
1	Simvastatin (Zocor)FDA LinkGeneric 03/2016
1	HIV Fusion InhibitorsIBA 03/2016
1	Amino Acids FDA Link 09/2015
1	Antiviral Agents (Antivirals)IBA 10/2014
1	Purinergic AntagonistsIBA 10/2014
1	Anti-HIV Agents (AIDS Drugs)IBA 10/2014
1	Proteins (Proteins, Gene)FDA Link 12/2013
1	Monoclonal AntibodiesIBA 07/2012
1	EpitopesIBA 07/2012

Therapy/Procedure

2	Therapeutics 01/2019 - 10/2014